先天性心脏病术后抗凝方案
该研究描述先天性心脏病术后标准化普通肝素抗凝方案的设计与实施效果,方案实施前后各前瞻性收集5个月临床结局。共792例手术患者中203例接受治疗性普通肝素,实施后临床相关出血事件减少(4.14 vs 1.62/100患者日;风险比0.39[0.20-0.75];P=.005),大出血和血栓事件发生率无显著差异。
要点
- 标准化普通肝素抗凝方案在先天性心脏病术后患者中可行。
- 方案实施后临床相关出血事件减少,风险比0.39(0.20-0.75),P=.005。
- 大出血(P=.88)和任何血栓事件(P=.55)发生率无显著差异。
核心结论
- 使用标准化抗凝方案是可行的,并可能降低心脏切开术后患者出血和血栓事件的发生率。
研究设计与样本
- 研究制定了先天性心脏病术后出血和血栓分层管理指南,对接受普通肝素治疗的患者使用抗Xa因子活性和活化部分凝血活酶时间进行剂量滴定。
- 在方案实施前后各5个月前瞻性收集包括出血和血栓事件在内的临床结局,并将事件判定为轻微、临床相关非主要或主要。
- 研究期间共随访792例手术患者,其中203例(实施前87例,实施后116例)接受治疗性普通肝素,共计1481患者日。
主要发现
- 203例接受治疗性普通肝素的患者中,28%为新生儿,35%为婴儿(29天至1岁),方案实施后新生儿减少和RACHS评分降低呈趋势。
- 在1321对时间匹配配对中,活化部分凝血活酶时间与抗Xa因子活性水平相关性差(r²=0.33)。
- 需要增加医疗护理(包括输血)的临床相关出血事件在方案实施后减少(每100患者日4.14 vs 1.62;风险比0.39[0.20-0.75];P=.005),校正年龄和RACHS评分差异后仍显著(P=.006)。
- 该发现主要见于RACHS 1至3类手术后(风险比0.27[0.10-0.73];P=.0099)和非婴儿(风险比0.25[0.09-0.65];P=.005)。
- 大出血发生率(P=.88)或任何血栓事件发生率(P=.55)无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients undergoing surgery for congenital heart disease are at high risk for bleeding as well as thrombosis in the postoperative period. The objective of the study was to describe the design and effects of implementing a standardized unfractionated heparin anticoagulation protocol for children after congenital heart surgery. METHODS: We created a tiered guideline for the postoperative management of bleeding and thrombosis. In patients treated with unfractionated heparin, anti-factor Xa activity level as well as activated partial thromboplastin time were used for dose titration. Clinical outcomes, including bleeding and thrombosis events, were prospectively collected for 5 months before and after protocol implementation and adjudicated as either minor, clinically relevant nonmajor, or major. RESULTS: Among 792 surgical patients followed during the study period, a total of 203 patients (87 preimplementation, 116 postimplementation) were treated with therapeutic unfractionated heparin over a total of 1481 patient days. Of these, 28% were neonates and 35% were infants (29 days to 1 year), with a trend toward fewer neonates and lower Risk Adjustment for Congenital Heart Surgery (RACHS) scores after protocol implementation. Among 1321 time-matched pairs, activated partial thromboplastin time and antifactor Xa activity levels were poorly correlated (r2 = 0.33). Clinically relevant bleeding events, which required increased medical care, including blood transfusion, decreased after protocol implementation (4.14 vs 1.62 bleeding events per 100 patient-days; risk ratio, 0.39 [0.20-0.75]; P = .005), even after correcting for differences in age and RACHS scores (P = .006). This finding was primarily found after RACHS category 1 to 3 procedures (risk ratio, 0.27 [0.10-0.73]; P = .0099) and in noninfants (risk ratio, 0.25 [0.09-0.65]; P = .005). There were no significant differences in the incidences of major bleeding (P = .88) or any thrombosis (P = .55). CONCLUSIONS: The use of a standardized anticoagulation protocol is feasible and might reduce the incidence of bleeding and thrombosis events in postcardiotomy patients.
引用
- Nair AG, Oladunjoye OO, Trenor CC, et al. An anticoagulation protocol for use after congenital cardiac surgery. J Thorac Cardiovasc Surg. 2018. PMID: 29706371. doi:10.1016/j.jtcvs.2018.02.106
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。